Speaker illustration

Doctor Jannick Dorresteijn

University Medical Center Utrecht, Utrecht (Netherlands (The))

Member of:

Jannick Dorresteijn studied Medicine (2009) and Clinical Epidemiology (2011) at Utrecht University. His PhD research focused on personalizing the treatment of cardiovascular diseases based on computational models. He conducted this research partly at Harvard University and led to a cum laude PhD at Utrecht University in 2013. He completed his training as an Internist, Specialist in Vascular Medicine at University Medical Center Utrecht, The Netherlands in 2019, and is currently still employed there. His research interests are cardiovascular prevention, prediction research, and premature atherosclerosis. Dr. Dorresteijn contributed to the development of several risk prediction apps, including https://U-Prevent.com and the ESC CVD risk calculation app. He is a member of the ESC Cardiovascular Research Collaboration working group and was listed as a final author on publications of guideline-recommended risk scores, e.g. SCORE2, SMART2, LIFE-CVD, and DIAL.

Implementing novel cardiovascular risk scores: are the challenges universal?

Event: ESC Preventive Cardiology 2023

Topic: Scores

Session: Geographic update of cardiovascular risk prediction tools: focus on Asia


Risk prediction tools in cardiovascular disease prevention - Commentary

Event: ESC Preventive Cardiology 2021

Topic: Risk Factors and Prevention

Session: Let´s look at 2020´s most cited articles in the European Journal of Preventive Cardiology (EJPC)


Individual lifetime treatment effect estimation in vascular patients: the new U-Prevent online calculator.

Event: EuroPrevent 2019

Topic: Cardiovascular Risk Assessment

Session: Using risk calculators for personalizing cardiovascular disease prevention: how, for whom, and when?


Predicting life-expectancy without recurrent vascular events in patients with cardiovascular disease: the REACH-SMART model

Event: ESC Congress 2018

Topic: Scores

Session: Challenges in improving risk prediction


Estimating preventive treatment effect in individual patients from a lifetime perspective: the aspirin example

Event: ESC Congress 2016

Topic: Primary cardiovascular prevention: interventions and outcomes

Session: Improving cardiovascular disease prevention


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb